(Total Views: 479)
Posted On: 07/11/2019 12:25:40 PM
Post# of 38

$CARA News Article - Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence -Engineered Oral KORSUVA(TM) for Pruritus in Patients with Atopic Dermatitis https://marketwirenews.com/news-releases/ente...22664.html


My Twitter: WhyteStocks